Spravato® (Esketamine) Treatment for Depression
Backed by Research, Covered by Insurance
Spravato®, an FDA-approved nasal spray administered in a clinical setting, offers a new treatment option for patients with treatment resistant depression who have not responded to other forms of treatment.
Being Health currently accepts:
What is Spravato® (Esketamine)?
Spravato® (esketamine) is an FDA-approved intranasal spray used either alone or in combination with an oral antidepressant to treat adults with severe depression that has not responded to other forms of treatment. Esketamine is a chemical component of ketamine that works differently than traditional antidepressants. Rather than targeting serotonin or norepinephrine, it acts on glutamate, one of the brain’s most abundant neurotransmitters.
What conditions can Spravato® (Esketamine) treat?
Spravato® (esketamine) intranasal spray is FDA-approved for use alone or in combination alongside an oral antidepressant to treat adults who have been diagnosed with the following conditions
Treatment-Resistant Depression (TRD)
Depression that does not respond to two or more antidepressant medications.
Major Depressive Disorder (MDD) + Suicidality
Depression with acute suicidal ideation or behavior.
What To Know About Spravato® (Esketamine) Treatment
Spravato® has been shown in numerous studies to provide rapid improvement in depressive symptoms in people with treatment-resistant depression.
Rapid Antidepressant
Effect
Can offer immediate relief from depressive symptoms, as well as a potential reduction in depression relapse rates.
Safety &
Clinical Monitoring
Guided by the highest safety standards, Spravato® (esketamine) is administered under the guidance of a clinician in our NYC office with ongoing monitoring.
FDA-Approved & Covered by Insurance
Spravato® has been FDA-approved since 2019, enabling many major insurance plans to cover Spravato® (esketamine) for patients with severe depression.
Spravato® (Esketamine) Treatment at Being Health
Our Spravato® program involves a comprehensive evaluation with a Being Health psychiatrist to determine eligibility, followed by the recommended Spravato® protocol.
Interventional Psychiatry Consultation
60 minutes
Experience Spravato® Treatment at our New York City space
We offer in-clinic Spravato® treatment at our Lower Manhattan location, designed with healing in mind.
Being Health | Lower Manhattan
11 Hanover Square, 18 FL, New York, NY 10005Entrance at 76 Beaver Street
A Mind-Body Approach to Spravato® Care
Being Health offers a unique approach to Spravato® care, offering complimentary acupuncture and nutrition sessions during the first 3 months of Spravato® care.
3 Complimentary Sessions
Studies have shown that acupuncture can reduce the severity of depression symptoms and can also enhance the effects of anti-depressants. Spravato® patients will receive 3 complimentary acupuncture sessions.
3 Complimentary Sessions
To optimize your mental health from a nutrition angle, Spravato® patients will receive 3 complimentary nutrition sessions.
“Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.”
How can I get started with Spravato® Treatment?
Book an Interventional Psychiatry Consultation
Schedule a consultation with a Being Health psychiatrist and complete our digital intake forms.
Meet with a Being Health psychiatrist
Meet with one of our licensed psychiatrists for a 60-minute evaluation to understand your history and see if Spravato® could be a fit for you.
Begin your
healing journey
If it is determined that Spravato® is a safe and appropriate option for you, we will develop your treatment plan.
FAQs
Is Spravato® covered by insurance?
Yes, Spravato® (esketamine) is FDA-approved and often covered by insurance, including most commercial plans. Coverage typically requires that certain clinical criteria are met, such as a diagnosis of treatment-resistant depression and a history of trying multiple antidepressants without sufficient improvement.
During your initial consultation, a Being Health psychiatrist will assess if Spravato® is right for you. If so, we’ll review your insurance coverage, determine any out-of-pocket costs, handle prior authorizations, and manage any paperwork for you.
Is Spravato® FDA approved?
Yes, Spravato® was first approved by the FDA in 2019 for use alongside an oral antidepressant to treat treatment-resistant depression (TRD) in adults—typically defined as depression that hasn’t improved after trying at least two antidepressants. Spravato® is also approved for adults with major depressive disorder (MDD) who are experiencing acute suicidal thoughts or behavior.
In early 2025, the FDA expanded its approval, allowing Spravato® to be used on its own, making it the first and only FDA-approved monotherapy for adults with TRD.
How does Spravato® work?
Spravato® works differently from common oral antidepressants. Rather than targeting serotonin, it targets the NMDA receptor, a part of the brain’s glutamate system involved in mood regulation and neuroplasticity. This unique mechanism can potentially lead to rapid improvement in symptoms and has been shown to be uniquely effective in individuals experiencing depressive symptoms that haven’t responded to other forms of treatment.
Do I have to go off antidepressants to receive Spravato® treatments?
No, you don’t need to stop taking your current antidepressant. Spravato® was originally approved to be used in combination with an oral antidepressant and was recently approved for use on its own. If Spravato® is right for you, our clinical team will review your current medications to ensure they’re safe and compatible with your treatment plan.
What is the difference between Ketamine and Spravato® treatments?
While both ketamine and Spravato® (esketamine) are used to treat depression, there are key differences in their formulation, administration, and FDA approval.
Spravato® is a nasal spray that contains esketamine, a modified form of ketamine. It is FDA-approved specifically for treatment-resistant depression (TRD) and for adults with major depressive disorder (MDD) and acute suicidal ideation or behavior. Spravato® must be administered in a certified medical setting under direct supervision, due to safety monitoring requirements.
Ketamine, by contrast, is most commonly administered via intravenous (IV) infusion and is used off-label for depression. While not FDA-approved specifically for mental health conditions, studies show that ketamine can offer rapid relief of depressive symptoms in some individuals.
Both treatments can be effective, but the right option depends on your symptoms, medical history, and treatment goals. At Being Health, our team will guide you through both options to determine what’s best for you.
How do I know if Spravato® is right for me?
Spravato® may be an option if you’re an adult living with treatment-resistant depression—typically defined as depression that hasn’t improved after trying at least two antidepressant medications. It may also be appropriate if you’re experiencing major depressive disorder (MDD) with acute suicidal thoughts or behavior.
At Being Health, one of our psychiatrists will meet with you for an initial consultation to evaluate your symptoms, treatment history, and overall health. If Spravato® is a good fit, we’ll guide you through every step—from insurance authorization to ongoing treatment and monitoring. What symptoms and conditions might improve with Spravato® treatment?
Spravato® is primarily used to treat treatment-resistant depression—a form of depression that hasn’t responded well to other medications. People often report improvements in symptoms like persistent sadness, hopelessness, fatigue, low motivation or even suicidal thoughts. It may also help with emotional numbness, anxiety related to depression, and difficulty enjoying daily life.
If you’ve been feeling stuck despite trying multiple treatments, Spravato® may offer a new path toward relief and healing.
What are the risks and potential side effects of Spravato®?
Like any medication, Spravato® can have side effects. The most common include dissociation (feeling disconnected from yourself or your surroundings), dizziness, nausea, sleepiness, increased blood pressure, and a sense of floating or spinning. These effects usually occur shortly after treatment and tend to wear off the same day.
In more severe circumstances it can cause slowed breathing and sedation. It also carries a risk of abuse/misuse. And Spravato® is not safe in individuals where a significant elevation in blood pressure would be dangerous, such as individuals with an aneurysm, stroke, intracerebral hemorrhage, and significant cardiovascular disease. It is also not approved for use during pregnancy. Additionally, like all antidepressant medications, Spravato® has an FDA warning that antidepressant medications may increase suicidal thoughts and actions in some people 24 years of age and younger.
Because of these potential risks and side effects, Spravato® is only available through a certified treatment center under the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program. This means it must be administered in a clinical setting with medical supervision who will carefully monitor your response to ensure your safety and comfort throughout treatment.
Is Spravato® addictive?
Spravato® (esketamine) has the potential for misuse or dependence, which is why it’s only available through a clinically monitored setting like Being Health, under medical supervision. However, when used as prescribed and administered in a clinical setting, the risk of addiction is considered low.
Our clinical team follows all safety protocols and monitors each patient closely before, during, and after treatment to ensure it’s used responsibly and effectively.
